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Abstract 
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Purpose: The purpose is to present a greater understanding of the progression 
of innovation capital in a technology transfer and biotech start-up 
context. The findings offer technology transfer professionals, 
entrepreneurs and academia an overall perception and mental 
framework of the technology transfer practice and the embracement 
of a promising invention, building upon its hidden value. 
 
Methodology: The thesis was conducted using a qualitative case study, executed with 
the help of interviews, in order to answer the research question: How 
is an embryo of innovation capital continuously cultivated in a 
technology transfer and biomedical start-up process? 
 
Conclusions: A technology transfer entity provides the means to establish a 
platform where an entrepreneur can build its own human capital, 
structural capital, and relationship capital. The forms of capital 
interact and thus create value, herein considered as innovation capital. 
Whilst the interaction is increased, the ability of renewal is improved 
and results start to amass, thus innovation capital is elevated. The 
results may be seen as an accumulated mass of explicit knowledge. 
The mass is in need of safeguarding in order to appropriate the rents 
from innovation and hence the use of patent protection is put into 
effect, turning intellectual assets into intellectual property rights. The 
value from this is derived from two aspects: commercial value of 
safeguarded explicit knowledge mass and degree of uncertainty. This 
matches up to the corporate valuing mechanism, market value added, 
argued to be the most appropriate in the intangible value chain. 
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1. Introduction 
This first chapter is intended to provide the reader with an understanding of the focal 
areas, the theoretical propositions in the problem discussion and lastly the purpose and 
scope of this thesis. 
1.1. Background 
This first section will provide the reader with an understanding of the biotechnology 
industry, why it is relevant to discuss it in the view of intellectual capital and the role 
of small ventures in the biotechnology sector. 
1.1.1. The biotechnology industry 
Fundamental discoveries, such as recombinant DNA and monoclonal antibodies, led 
to the emergence of biotechnology in the 1970s, something that was followed by 
several industrial applications (Saviotti et al., 2005). The biotech industry consists of 
firms operating in various sectors such as health care, environmental, agri-food and 
aquaculture. For those firms involved in scientific discovery aimed at the creation of 
new health care products, the process is lengthy and challenging. Discovery and 
preclinical studies are followed by three phases of clinical trials on humans thereby 
obtaining required regulatory approval. The development period of biotech products 
are among the longest of any science- or technology-based product, reportedly taking 
six to eight years in reaching a regulatory approval (Cumby & Conrod, 2001). The 
three phases of clinical trials are intended to ensure safety when a substance is applied 
as human treatment, defining appropriate dosage and the discovery of possible side 
effects. Naturally, the number of individuals subjected to the trials increase by each 
phase, normally 20-80 in a phase I study, followed by 100-300 and finally 1000-
3000 individuals in phase III (National Institute of Health, 2006). 
Sweden has the potential to become one of the world leaders in research and 
entrepreneurship within the biotech industry. Currently there are approximately 800 
active companies with 40 000 employees working with developing new products and 
services related to biotech (Vinnova, 2005). Although there are numerous hurdles for 
biotech firms to evade during development of a product, the biotech industry is an 
archetype of industries with forecasts for astonishing high future sales (Hermans & 
Kauranen, 2005). As a result of its good future prospects, the biotechnology industry 
has attracted vast amount of financial support from various venture capitalists and 
institutions which in turn has spurred a growth within the field (Vinnova, 2005). 
As an example of the potential value in the biotech industry we can highlight 
Esperion Therapeutics, founded in 1998 by a group of researchers, which develops 
drugs inhibiting progression of atherosclerosis by reducing arterial plaque in certain 
heart patients. After positive phase II trial results, showing that one of their drug 
candidates were safe and well tolerated, Esperion Therapeutics was bought by Pfizer 
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in 2004 for an estimated $1.3 billion. However, a product launch is not expected 
until 2007, thereby making Esperion Therapeutics profitable by 2008 (Mullin, 
2004).  
1.1.2. The Intellectual Capital perspective 
If we consider the case of Esperion Therapeutics, there is obviously a tremendous gap 
between book and market value of such a firm. This phenomenon is on the other 
hand the essence of intellectual capital (IC). IC is in its most basic sense defined as 
the difference between book value and market value (Edvinsson & Malone, 1997). 
Edvinsson (2002) further describe IC as the future earning potential of the 
organization and in short the ability to transform knowledge and intangible assets 
into value, by multiplying human capital, the knowledge and brains of the people 
who work for the organisation, with structural capital, the work processes, routines, 
office design and the like. Thus applying an IC perspective to this industry might 
help in clarifying how to manage and build the potential, yet hidden, value in these 
firms.  
After all, intangible assets are the primary drivers of wealth and growth in 
modern economies. Thus, dominant market positions, abnormal profits and even 
monopolistic advantages are most effectively obtained by the management of these 
intangible assets (Hand & Lev, 2003). 
How may these intangibles be properly managed and safeguarded then? Biotech 
firms, like any science-based, technological sophisticated industries, need to 
appropriate the returns on their innovations and therefore must protect their 
intellectual assets (Cohen et al., 2000). The appropriation regime most widely used 
by biotech firms is patents. Research shows that patent protection for pharmaceutical 
and biotech products is unusually strong. This is mainly due to the precise chemical 
definition of the patented innovation, which is difficult to circumvent by rivals and 
therefore easier to defend against infringements in court (Calabrese et al., 2000). 
The overall idea of managing intellectual and intangible assets also commonly 
falls under the IC concept. As mentioned, the dominating appropriation regime and 
protection of intellectual assets used by biotech firms is patenting; naturally we want 
to understand where and how patenting is a feature in the IC landscape. Edvinsson 
& Sullivan (1996) discuss a model for managing IC and begin by defining the two 
components of IC as human resources and structural capital, which include 
intellectual assets. The distinction of the two is important to company owners. 
Intellectual assets are pieces of codified knowledge that, unlike human resources, can 
be owned by the firm. Hence, the transformation of innovations produced by the 
human resources into intellectual assets is of crucial importance. Intellectual assets of 
great value or those to be used outside of the firm are likely in need of protection. 
When intellectual assets receive legal protection, for example by patenting, they 
become intellectual property. 
Granstrand (1999) discusses the rise of IC firms and IC-intensive industries, 
defining an IC firm with the characteristic of a build-up and exploitation of 
immaterial resources and the concern of turning these resources into capital for 
economic purposes. Firms can be classified according to the share of IC and it is 
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possible to find almost ‘pure’ IC firms, in which IC is the only productive factor. The 
numbers and types of these firms are growing; consequently more ‘pure’ IC industries 
arise, for example the biotech sector. As a result of this we can see that generating 
value in the biotech industry is to a great extent about managing the IC. 
1.1.3. Small Biotechnology ventures  
To elaborate on the role of start-up firms within the biotech sector, Granstrand 
(1999) also brings up that in almost ‘pure’ IC industries new start-up firms, both 
autonomous start-ups firms and corporate ventures, are naturally becoming IC-
oriented and that new start-ups play a fundamentally important function of 
intellectual capitalism.  
Zahra (1996) studied start-up biotech firms in the U.S. and compared the 
performance of autonomous ventures (AV) versus corporate ventures (CV). The 
results showed that AVs outperform CVs and that there might be many possible 
explanations. Founders of autonomous ventures are more interested in the fate of the 
venture, since their wealth depends on its success, and are often closely involved in 
the operation, which in turn creates an environment where risk-taking is encouraged. 
Resource advantages of corporate ventures may not always generate competitive 
advantages. CVs frequently encounter difficulties accessing resources from corporate 
sponsors; they may become caught up in political and budgetary processes or 
constrained by existing systems and policies. Altogether, AVs may do better because 
emerging high technology industries, such as biotech, require radical innovation. 
1.2. Problem discussion 
In the background we have presented the essential facts to be used in the following 
problem discussion and theoretical propositions. We can see that the biotech industry 
is a promising sector that clearly benefits from small autonomous start-up firms. The 
background also brought a discussion on the benefits of applying an IC perspective 
on biotech firms. 
1.2.1. Value from Intellectual Capital 
Harrison & Sullivan (2000) describe how firms profit from their IC. The value of a 
firm’s IC depends on the company’s context, which is expressed through the vision of 
what they wish to become and the strategy of how to achieve it. Different companies 
will determine different roles for their IC, which in general is divided into offensive 
and defensive roles. How IC is managed may also be considered regarding its impact 
on a current or a future time dimension. Extracting value from intellectual assets 
normally involves thinking of the future and about strategic positioning. Intellectual 
capital can be a source for either one-time transaction value or an ongoing cash-flow-
producing value, although IC assets are often sold individually or in bundling. 
As we observed in the Esperion Therapeutics case the value is realized after a 
number of years, hence in a future time dimension. This brings us to think of a 
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decision that has to be included in the vision for small biotech companies, i.e. 
whether to sell the intellectual asset or commercialize it on your own? To 
commercialize it on your own usually requires additionally resources or capabilities. 
Edvinsson & Sullivan (1996) refer to this as complementary business assets, such as 
processing facilities, service forces or distribution networks. The concept of 
complementary assets was however introduced by Teece (1986), showing the 
importance of having a complete set of business assets when deploying an innovation.  
Lacking complementary assets and the ability to obtain them, naturally leaves the 
firm with the option of selling or licensing the intellectual asset to another firm with 
the appropriate set of complementary assets. This scenario is also usually displayed in 
the biotech industry, not least with the example of Esperion Therapeutics, where 
larger multinational firms purchase small companies having achieved certain 
promising research results. Making clinical phase III trials as well as launching 
products commonly requires relatively large amounts of capital, hindering small 
biotech firms from going all the way on their own. 
If the most reasonable future for a small biotech firm is to be purchased by a 
large corporation, what is the value being derived from the almost ‘pure’ IC firm? An 
intangible asset is an abstract concept, yet Ahonen (2000) makes a distinction 
between generative and commercially exploitable assets in the intangible value chain. 
The value chain depicts that generative assets, human and structural capital, produce 
commercially exploitable assets, such as patents, which in turn are valued by the 
market; claiming that market value added is the preferred measurement of derived 
value from intangible assets.  
This perspective is almost equivalent with the concept of innovation capital, a 
subunit of structural capital in Skandia’s value scheme, reflecting the renewal 
capability as well as the result of that capability in the form of intellectual property 
rights (Edvinsson & Malone, 1997). Innovation capital is also proclaimed to be the 
pivotal link of IC in recent studies, simply stressed by the importance of an ability to 
innovate for increasing corporate value (Tseng & Goo, 2005; Chen et al., 2004). 
Thus we may observe that value in commercially exploitable assets is a product of 
time. This creates a reason to believe that the management of innovation capital over 
time, i.e. both the ability to innovate and the result of this effort, is a means of 
achieving value maximization, in this sense. Having comprehended this logic it leads 
us to the question of how this is done? 
1.2.2. The Technology Transfer process  
New biotech start-ups are predominantly founded on the basis of novel inventions 
generated by academic research. As a result, biotech firms are mainly localized around 
universities offering high quality and biomedical research. In Sweden, university 
researchers are granted the intellectual property right of their inventions and 
inventors can choose if to commercially exploit it, including which route for 
technology transfer they wish to utilize. In order to improve exploitation of 
knowledge from universities, and thereby promote regional growth, 
Teknikbrostiftelsen was established in the mid 1990s at seven universities around 
Sweden. The purpose of Teknikbrostiftelsen is to help researchers carrying an 
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invention with preparing a business plan, patenting, licenses and founding (Medicon 
Valley Academy, 2004).     
In addition to the above mentioned technology transfer process, a discussion 
with Stina Gestrelius (2005), Vice President of Medicon Valley Academy, provided 
us with the following insight regarding the development of a business and patenting 
in small biotech ventures. The management of a smaller firm within the biotech 
industry usually does not have sufficient knowledge or the resources needed to 
manage and create strategies related to business and patenting. As a result of this, the 
firm continuously turns to intellectual property bureaus, seeking assistance with for 
the most part patenting.  
1.2.3. Problem summary 
Now we may be able to see that exploiting novel inventions and knowledge, with 
regards to biomedical science, i.e. intangible assets steamed from an academic 
research environment, is a question of managing IC and in particular innovation 
capital.     
In the problem discussion we can observe two different aspects that are 
interesting regarding management of IC in small biotech firms. Firstly, there is the 
intrinsic problem with six to eight year long periods of product development that is 
to be followed by commercialization. Autonomous ventures seam to create a better 
environment in emerging high technology industries, where there may be a need for 
radical innovation. However when products are to be commercialized small firms 
may lack complementary assets, which can inhibit a successful product launch. A 
solution is to pursue a strategy where the whole company or just the specific product 
is sold or licensed to a larger firm with a right set of complementary assets. This in 
turn needs to be considered early in the process of converting innovations into 
intellectual assets and safeguarded through patenting in order to maximize the value. 
By looking at the past discussion on IC, it is evident that managing the build up of 
innovation capital is a mean of achieving this value maximization. 
Secondly, since founders of small biotech firms often lack knowledge and 
resources to manage their IC, they frequently turn to external agents such as 
Technology Transfer agents and intellectual property bureaus. The fact that external 
parties to a large extent are involved in the IC management is also interesting. Not 
least just to determine their roles in the perspective of IC management.    
1.2.4. Research question 
The focal subject is the apprehension of how innovation capital is developed and 
increased. Comparing a novel invention and its inventor with an embryo of 
innovation capital; how is it managed and safeguarded in order for it to prosper into 
tremendous value, hoping to achieve similar figures as in the case of Esperion 
Therapeutics? With regards to the problem discussion, this may be summarized into 
the following question:  
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“How is an embryo of innovation capital continuously cultivated in a 
technology transfer and biomedical start-up process?” 
1.2.5. Purpose 
The purpose is to present a greater understanding of the progression of innovation 
capital in a technology transfer and biotech start-up context. The findings offer 
technology transfer professionals, entrepreneurs and academia an overall perception 
and mental framework of the technology transfer practice and the embracement of a 
promising invention, building upon its hidden value.  
Our research question incorporates studying biomedical start-up. This is by all 
means an important and comprehensive part of the biotech industry, yet not covering 
all the various types of technologies within the concept of biotech. The purpose of 
selecting a biomedical case is primarily due to wanting to capture the intrinsic time 
conditions created with product development lasting up till ten years or more, not to 
focus on a specific area of technology. 
Visualizing Innovation Capital: A case study of Technology Transfer and Biomedical start-up 
 
 7
2. Methodology 
In this chapter we describe the methods that have been used and how we have approached 
the research questions in a scientific manner. 
2.1. Research method 
As an introduction to how this thesis came about, the first part will describe the 
initial phases and the overall approach of the study. The second part emphasizes why 
we have chosen a qualitative research method. 
2.1.1. Approach 
Previous experience of studying intellectual property rights, along with the apparent 
importance of the Intellectual Capital concept in modern economies, brought us to 
an early decision of writing a thesis on some aspect IC. We also realised that it would 
perhaps be more interesting to limit the scope of the thesis to a particular industry, 
one where intellectual assets are of substantial importance. We recalled a guest lecture 
given by Stina Gestrelius, Vice President of Medicon Valley Academy, on the Biotech 
industry and a choice was made. After a thorough literature review on the area of IC 
and its application to the Biotech industry, combined with an interview with Stina 
Gestrelius (2005, we arrived at the problem formulation and research question you 
find outlined in chapter one. Thus we have based much of our initial perceptions and 
propositions on previous studies and theory, yet it is still intertwined with empirically 
gathered data from a discussion with an industry expert working with firms in the 
biotech industry. 
In research there are generally two approaches whereby theory and empirical data 
relate to each other, namely the inductive and deductive approach. Using an 
inductive approach, a researcher gathers data without any preconceived thoughts or 
hypotheses and from this data new theories are created. With a deductive approach, 
the researcher creates a theoretical framework, which is then verified using data 
gathered from field research (Wallén, 1996). Conducting a ‘pure’ inductive or 
deductive study is however difficult and both approaches have been criticised for 
their shortcomings. Therefore, today one rather speaks of the degree of openness in 
the approach, taking into account the boundaries a researcher has set before the data 
is to be gathered and how open the researcher is for new and unexpected information 
which was not considered in advance (Jacobsen, 2000). 
 If we are to characterize the approach, the process has been to a large extent 
deductive, drawing upon results from previous studies and using a theoretical 
analytical framework. However to fill some of the knowledge gaps identified our 
approach also includes elements of an inductive nature; concerning the role played by 
external parties, where we found little previous studies related to the area of IC and 
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small venturing. On the other hand, our mapping of this relatively uncharted matter 
was to some extent influenced by the notion we had on how small biotech firms start 
out and develop, which from a ‘pure’ inductive perspective is less accurate. 
Summarised, we have set relatively clear boundaries while leaving some room for 
unanticipated data.       
2.1.2. A qualitative study  
Conventionally there are two methods of conducting scientific research, 
quantitatively and qualitatively. The choice of method is governed by the purpose of 
the research and to some extent by the science itself (Yin, 2003). The strengths of the 
qualitative method are many but foremost the richness and holism of the data 
collected, thus enabling a deeper understanding (Miles & Huberman, 1994). 
Due to the descriptive nature of our purpose and the need for comprehensive 
and in-depth empirical data to answer the research questions, we found that a 
qualitative approach is highly suitable. If we were to conduct a quantitative study, 
previously uncharted issues embedded in the research propositions, expected and 
unexpected, would be neglected, not to mention the numerous vague assumptions 
that would have to be made in order to formulate hypotheses to be tested. Our 
decision to perform this study with a qualitative toolset has on the other hand 
implications on the reliability and validity of the results, which we discuss further in 
section 2.5 Validity & Reliability.  
2.2. Case study 
The case study is a widespread strategy in qualitative social science research. Yin 
(2003), describe the methodology which is basically characterised by the in-depth 
study and analysis of one or a few units. 
2.2.1. Design 
In its most basic sense a research design is the logical sequence that connects the 
empirical data to a study’s initial research questions and in the end, its conclusions. 
Five components of a research design are especially important: (1) a study’s 
questions, (2) its propositions, if any, (3) its unit(s) of analysis, (4) the logic linking 
the data to the propositions, (5) and the criteria for interpreting the findings (Ibid.). 
Regarding the first two set of components, the research question and theoretical 
propositions of this thesis are outlined in chapter one. While addressing the third 
component, the case definition needs to be clear. In qualitative research one often 
struggles with a definition of the case, although abstractly it can be defined as a 
phenomenon of some sort in a bounded context (Miles & Huberman, 1994). The 
case definition used in this study is, to be more precise, the management of 
intellectual assets and enhancement of its potential value, during the technology 
transfer process and continuously in the development of a small Biotech firm. While 
the case definition refers to the management of IC in fostering the innovation capital, 
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belonging to a firm, the actual course of action involves several other actors who take 
part in different decisions and activities. As a consequence, the units of analysis used 
in the case study are the small biotech firm, the intellectual property agents, the seed 
capital firm and the business development firm. Yin (2003) labels the usage of 
multiple units of analysis while still focusing on one case as an embedded single case 
design. The selection of units of analysis and data collection sources of each unit is 
discussed in the next part. The fourth and fifth components of the case design are 
discussed in section 2.2.3 Data analysis. 
2.2.2. Gathering of Data 
The selection of units of analysis originates in the development of a small biotech 
firm named Cartela AB. The firm was founded in the year 2000, currently has 13 
employees, conducts research in biomedicine and pursues an outspoken strategy to 
generate revenue by corporate collaborations and by out-licensing its technology. 
There is also a plan for an exit within 5-7 years by trade-sale to another 
pharmaceutical or biotech entity (Cartela, 2005). Evidently this is a small company, 
with a relatively short track record, pursuing a formulated strategy of collaboration 
and out-licensing as well as a vision of a planned exit. Thus, this firm is a good 
research candidate and a choice Yin (2003) would describe with a representative or 
typical case rationale. Cartela AB is naturally one of the units of analysis.  
As mentioned, three external firms have significantly contributed to the initial 
growth of Cartela AB (Innovationsbron Syd, 2005); logically they are also regarded as 
units of analysis. Teknoseed AB made partial initial investments to support research 
and development. Essential developments of the business plan as well as the 
establishment of key contacts where made with the help of Teknopol AB. 
Forskarpatent i Syd AB provided help in the pre start-up phase of Cartela AB, selling 
the invention to an industry actor. All three are subsidiaries of the overarching 
organisation named Innovationsbron Syd AB, formerly known as Teknikbrostiftelsen 
i Lund, which have a coordinating role. Finally, two of the selected units of analysis 
are intellectual property bureaus. Awapatent AB was the agent providing assistance 
when submitting the first two patents in Cartela AB’s portfolio. In an effort to 
reinforce the study’s ability to capture the importance of patenting in relation to 
business strategy, we also selected Wagner Zacco AB, claimed to be the leading IPR 
bureau in Scandinavia, as a unit of analysis.    
Yin (2003) also discusses how to prepare for data collection in a case study. 
Whilst the data collection may have to rely heavily on information from individual 
interviewees, conclusions need to be supported by other sources of information, for 
example organizational outcomes or corporate documentation. Such information is 
of course used in our case study and is continually presented in the case description 
found in chapter 4. For example the empirical chapter includes a walkthrough of the 
patent documents. However, the primary data collection sources in the units of 
analysis are the individuals listed below. Although each unit of analysis contains very 
few employees, in order to obtain the best information we stated our area of interest 
and requested the most appropriate informed interviewee. 
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Sources of data collection within the units of analysis: 
 
• Evy Lundgren-Åkerlund, inventor, founder and CEO, Cartela AB 
• Adam Schatz, former Board Member, Cartela AB, and Managing Director, 
Teknoseed AB 
• Per Antonsson, Business Advisor, Teknopol AB 
• John Karlström, Patent Attorney, Awapatent AB 
• Sven Trolle, CEO, Forskarpatent i Syd AB 
• Sven-Thore Holm, CEO, Innovationsbron Syd AB 
• Per Tomas Karlsson, Managing Director, Wagner Zacco AB 
 
The interviews conducted have been relatively unstructured or open in character. 
Thus the interviewees were given room to answer questions and describe events in 
great detail (Kvale, 1997). During our interviews, the answers were succeeded by 
more probing questions for the purpose of elaboration, which led to a dynamic 
interview process. This is a common characteristic and a strong point of case studies 
according to Yin (2003). Kvale (1997) recommends the usage of a tape recorder 
during interviews; it enables the researcher to concentrate on the subject and the 
dynamics of the interview. On the other hand, the usage of a tape recorder might 
interrupt the conversation and the work effort afterwards, the process of transcribing 
the content, can be laborious, something that is often forgotten by researchers 
(Wallén, 1996). Having performed interviews with a tape recorder previously and 
considered the advantages and disadvantages, we saw that the benefits outweighed 
the negative effects.   
2.2.3. Data analysis 
When we conducted the analysis we used transcriptions from the interviews as 
working material for coding. The working material comprised of approximately 90 
pages in total. A code is a label attached to a piece of collected data, which in turn 
makes it possible to structure data. The process enables the researcher to gather data 
referring to certain codes and thereby draw conclusions (Miles & Huberman, 1994). 
For example we used the labels ‘patent claim’ and ‘patent scope’ to identify relevant 
data gathered from the data sources. The use of labelling enabled us to sort and 
summarise data, helping the process of writing the empirical chapter as well as 
drawing conclusions.   
     Relying on theoretical propositions and thinking of rival explanations are two 
primary analytical strategies described by Yin (2003) that we have used in the 
analytical process. Relying on the theoretical propositions initially formulated helps 
the researcher to focus on essential data and ignoring other data. It also helps to 
organise the entire case study and even formulate alternative explanations, which in 
turn can be considered. To support this process we have also used descriptive ways of 
visualising data as described by Miles & Huberman (1994), such as partially ordered 
displays, Role-ordered displays and conceptually ordered displays. For instance we 
built a comprehensive matrix with all the data sources on one axis and the time line 
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for Cartela’s start-up on the other. This helped us to charter the progression of the 
company as portrayed by the different interviewees. The displays were of course also 
used to write the empirical chapter, providing the reader with a coherent description 
of the case.   
2.2.4. Reporting 
An important decision early in the research process is to consider what impact one 
wants to have on the reader. The report is also used to strengthen the reliability and 
validity of the results (Miles & Huberman, 1994). As a familiar structure will ease the 
reading process, when a study is to be presented the structure should be adapted to 
the audience in mind. Most common in academia is the linear-analytic structure; 
introduction with background and research questions, methodology, literature 
review, presentation of empirical data with a discussion, followed by research results. 
A single case study is appropriately reported in a descriptive storytelling manner, 
complemented with graphics and tables (Yin, 2003). 
Our study aims to provide company founders as well as academia with an overall 
perception and mental framework of how to manage IC and foster an embryo of 
innovation capital in a Biotech industry setting. In view of that, the report is 
structured in a way that is familiar to academia, yet we have provided numerous 
examples in the case description, which hopefully will appeal to industry 
practitioners. The report also contains a detailed explanation of the research process 
in order to enhance the reliability of the study. 
2.3. Research quality 
The two concepts validity and reliability are central when determining the academic 
quality of research (Bryman, 1997). Yin (2003) discusses this in more detail and how 
it applies for case studies by describing four tests commonly used to establish the 
quality of any empirical social research: construct validity, internal validity, external 
validity and reliability. The four tests are used to reflect on the quality of this thesis. 
2.3.1. Validity 
Construct validity refers to the establishment of correct operational measures for the 
concept to be measured. Criticisms of case studies often mention that investigators 
fail to develop operational sets of measures and that ‘subjective’ judgement is used to 
collect data. One tactic to counter this is to establish a chain of evidence, i.e. to show 
the reader how research conclusions were derived from data mapped back to initial 
questions. When presenting the case and the research results, we have tried to provide 
sufficient details in order to clearly illustrate the derivation. Another tactic to increase 
the construct validity is to have a draft of the case study reviewed by a key informant. 
We adopted this procedure by letting four of our interviewees read a draft of the 
thesis and return comments. 
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Regarding internal validity, this only applies for explanatory case studies where 
the investigator tries to determine that event x led to event y. Hence, this test is of no 
relevance to our research. 
The external validity test is on the contrary very essential, dealing with the 
problem of knowing whether the study’s findings can be generalized beyond the 
current case study. This is the most common problem mentioned by critics of case 
studies, typically stating that single cases provide a poor basis for generalizing. 
However, that implies that the situation can be contrasted to survey research, where a 
sample readily generalizes to a larger population, which is incorrect. Survey research 
relies on statistical generalization, whereas case studies are to rely on analytical 
generalization; a method where the investigator is working to generalize a specific set 
of results to some broader theory.  
The domain to which our results are being generalized, on the whole, consist of 
the IC theories described in the analytical framework. This is done in the discussion 
of the empirical results in chapter 5. Additionally chapter 5 includes a discussion of 
the results with regard to explanatory power and relevance, thus concluding the 
generalization beyond the scope of this thesis. On the other hand, analytical 
generalization is also based on replication logic, meaning that the results need to be 
tested by replicating our findings in a setting where they should occur. Such 
replications have not been done by us, due to the limited extent of the thesis, but 
may provide a basis for further research.   
2.3.2. Reliability 
The objective of the reliability test is to make certain that if a subsequent researcher 
followed the same procedures as described by us and conducted the same case study 
again, the researcher would arrive at the same findings. The ultimate goal of 
reliability is to avoid or minimize errors and bias in the study. To address this 
problem, we have in this report tried to include all decisions made as well as research 
methods and procedures used.  
2.4. Ethical issues 
There is a close connection between ethics and the requirement of high quality in 
research. The basic fundamentals are not to obstruct the personal integrity of the 
individuals involved and to follow scientific norms, such as to undoubtedly show 
what is to be considered own efforts as opposed to works of others. Likewise, taking 
responsibility of how the research results might be used for various purposes is 
another must (Wallén, 1996). Concerning the personal integrity of interviewees, 
Miles & Huberman (1994) discuss informal consent, which means that involved 
persons are aware of the intention of the study and participate out of free will. This 
may be difficult due to the fact that the set research direction may be altered during 
the course of the study. 
First of all we can mention that all interviewees were informed about the thesis 
and the purpose of it. The research has been slightly altered as new data was gathered, 
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although not to such an extent that we abandoned the overall purpose and research 
focus. They were also asked for permission to record what was said during the 
interviews. We have as well been very careful to point out the work of others in this 
report. Regarding the potential usage of the results for various purposes, we have 
taken that into account and for instance deliberately avoided to use statements made 
by six out of seven interviewees in the case description, thus proving a high ethical 
awareness. 
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3. Theoretical analytical framework 
This chapter presents the framework used in case data collection and case discussion. The 
first section discusses the concept of IC and how it creates value. In the second section we 
describe the protection of intellectual assets, thus the main concepts regarding patenting as 
well as related strategies to consider.  
3.1. The Intellectual Capital concept 
The following discussion provides a description of the perception of intellectual 
capital (IC) used in our research. The concept may be difficult to comprehend, not 
least because different authors define the concept inconsistently. Therefore we have 
made an effort to interlink the models we have chosen to utilize in this study. 
3.1.1. Forms of capital   
Intellectual capital is in its most basic sense defined as the difference between book 
value and market value (Edvinsson & Malone, 1997). Edvinsson (2002) depicts that 
IC should be regarded as the future earnings potential of the organization; therefore 
it is about the flow rather than the stock, which is one of the common 
misunderstandings regarding the entire notion of IC. More lucidly, IC is the 
combination of human capital, the knowledge and brains of the people who work for 
the organisation, and structural capital, the work processes, routines, office design 
and the like. It is in essence having the ability to transform knowledge and intangible 
assets into value by multiplying human capital with structural capital. 
Included in the term human capital are individual capabilities, knowledge, skills 
and experience embodied in the people working in an organisation. In addition, it 
also comprises how the intelligent organisation adapts to a changing environment. 
For example how the people of the organisation upgrade their skills and how those 
new skills are leveraged. How are new skills as well as older experiences being shared 
with the rest of the organisation? Another aspect of great importance and included in 
human capital is the creativity and innovativeness of the organisation (Edvinsson & 
Malone, 1997). 
To define structural capital straightforwardly, it is what remains in the company 
when people go home (Edvinsson, 2002). It can also be defined as the empowering 
and supporting infrastructure of human capital. For example systems used to 
transmit and store intellectual material, organizational concepts, processes and 
documentation. Obviously, it contains a number of various components, which has 
resulted in efforts to dissect IC into subcategories of structural capital as well as new 
capital forms. An example of this dissection is the Skandia Market Value Scheme 
(figure 3.1), where structural capital can be seen to comprise customer capital and 
organizational capital, which in turn consists of innovation capital and process 
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capital. Organizational capital refers to the systems, processes and operating 
philosophy that facilitate the flow of knowledge through the organisation. It is the 
codified know-how in the organization as well as the process to leverage that 
capability. Subsumed in organizational capital is innovation capital, referring to the 
renewal capability and the result of innovation in the form of intellectual property, 
such as patents or other intangible assets used to create and bring innovations to the 
market. Process capital refers to work processes and employee programs that enhance 
the efficiency, the manufacturing and delivery of products and services. The customer 
capital is also subsumed under the structural capital and refers to the value of 
customer relationships, which may be described in terms of loyalty and satisfaction 
(Edvinsson & Malone, 1997).    
 
Figure 3.1 Skandia Market Value Scheme (Edvinsson & Malone, 1997, p. 52). 
 
However, Saint-Onge et al. (in Edvinsson & Malone, 1997) describe a model of IC 
where customer capital is hauled out from structural capital and placed as a separate 
form of capital equivalent to human and structural capital. The model emphasizes 
that it is the intersection of the three dimensions that form the basis of value creation. 
The IC model with three forms of capital is also a common assembly in recent 
studies on the topic of IC (Hermans & Kauranen, 2005). The rationale is described 
in the next section which focuses on value creation. 
3.1.2. Creating value 
Hermans & Kauranen (2005) show the value creation potential of IC in Finnish 
biotech companies, using a theoretical division of IC into three partly overlapping 
forms of capital (figure 3.2), namely human capital, structural capital and relational 
capital. Their perception of IC is built on the value creation platform model of Saint-
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Onge et al. (in Edvinsson & Malone, 1997) and modified in coherence with a 
definition of IC presented by the MERITUM project 2002. Their modified model 
adds to the three capital forms. For instance relational capital is an expansion of 
customer capital, having a wider scope to stress relations with suppliers, academic 
research networks and partners. With regards to relations, Edvinsson (2002) also 
emphasizes that relations work on two levels: the corporate and the personal level, i.e. 
relations belonging to the individual may leave the company together with the 
employee and can thus not be owned by the firm. Furthermore, Hermans & 
Kauranen (2005) underline the structural capital, which indicates the company’s 
capability to manage its activities in order for tacit knowledge to be converted into 
intellectual property rights.  
 
Figure 3.2 The IC Value platform (Hermans & Kauranen (2005), modified from Saint-Onge 
et al. in Edvinsson & Malone, 1997). 
 
As mentioned, in the model by Saint-Onge et al. it is the balanced intersection of the 
three dimensions that serve as the basis for value creation. To further elaborate on the 
value creation of IC, Hussi & Ahonen (2002) argue a close relation between the 
value creation platform model and the intangible value chain model.  
The intangible value chain is presented by Ahonen (2000) and is a classification of 
intangible assets into generative and commercially exploitable intangibles. Ahonen 
(2000) argues that the definitions discussed in the IC literature mixes these two types 
of intangibles and as a result obscures the value creating mechanism in a knowledge 
organisation. Portrayed in the intangible value chain model (figure 3.3) is that 
generative intangibles, consisting of human capital, internal structures and external 
structures, through interaction generate commercially exploitable assets. Examples of 
commercially exploitable intangibles in this perspective are intellectual property 
rights and reliable management. Thus Ahonen (2000) also recognizes the importance 
of achieving a balanced interaction between generative intangibles.  
To assess the economic efficiency, Ahonen (2000) argues that MVA (Market 
Value Added), i.e. the difference between market value and invested capital, is a 
better measure than for instance EVA (Economic Value Added), which is based on 
historical records and thus trusts that the future is like the past. The capital market is 
assumed to consider the effects of all known phenomena regarding the economic 
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performance of a company in a relevant future. Here the behaviour of the capital 
market is treated as a metaphor of what occurs in all kinds of businesses, actually in 
all kinds of organisations, regardless of them being traded in the stock market or not. 
Assumed is that those changes happening amongst companies traded on stock 
exchanges happen in other businesses as well. In this perspective MVA can be a useful 
measure of shareholder value and long term economic performance, although it is 
admitted to being an imperfect measure as well.  
 
 
 
Figure 3.3 The intangible value chain (Ahonen, 2000). 
 
To conclude the intangible value chain, the capital market’s expectations of the 
company performance are reflected in the firm’s market value. In turn the market 
value is in essence depending on the firm’s commercially exploitable intangibles, 
created in the balanced interaction of the generative intangibles. The thought of 
keeping commercially exploitable intangibles separate resembles the notion of 
innovation capital, which here can be viewed as a third angle on value creation with 
tight linkage to both models already discussed.     
We have already seen the term innovation capital described in Skandia’s market 
value scheme. However, Chen et al. (2004) argue that innovation capital should not 
be seen as a part of the structural capital, stressing the importance of innovation in 
the new economic era where it is a key factor for a company, enabling it to maintain 
a positive long-term competitive performance. Therefore innovation is not a subject 
to structural capital; in fact it is argued to be the pivotal link of IC. Stressing the 
integrative perspective of IC, Chen et al. (2004) place innovation capital at the core 
of IC and show a remarkable relationship between the four IC elements (figure 3.4). 
  
Figure 3.4 IC structure (Chen et al. (2004), p. 202) 
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Tseng & Goo (2005) also regard innovation capital as the fourth pillar of IC and 
relate the interaction between the elements to corporate value; underlining the 
importance of the ability to innovate in the effort to increase corporate value. 
We have now described closely related perspectives of value creation: the value 
platform, the intangible value chain and innovation capital as the pivotal link of IC. 
When comparing the three perspectives it is evident that intellectual capital is 
comprised of three forms of capital which have to interact in order to achieve value; 
with the interaction illustrated in the IC value platform and the corresponding 
concept of generative assets in the intangible value chain. It is also suggested that 
innovation capital is actually what is being generated in this interaction and that it, as 
a part of the IC landscape, should be regarded as the future earnings potential and 
therefore treated as a separate entity. Consequently the notion of innovation capital, 
being treated as a detached form of capital, is comparable to the idea of commercially 
exploitable assets and the derived marked value added shown in the intangible value 
chain. But, just to make the terminology clear, we may note that the intangible value 
chain uses the terms internal and external structure, however still implying the 
meaning of structural and relational capital. Likewise we see that the IC structure 
described by Chen et al. (2004) still uses the term customer capital. Naturally this 
may add to the confusion, however Hussi (2004) comments on the fact that different 
authors use different theoretical terms on the three dimensions; ultimately saying that 
it does not matter as long as the essence in the discussion on IC is the ability to 
provide a holistic view on organizational development. 
3.2. Protecting intellectual assets 
To elaborate further on the concept of intellectual capital, and especially innovation 
capital, in the biotechnology industry, we need an understanding of patenting and 
related concepts. 
3.2.1. Patenting criteria and procedure 
A prerequisite for the development of new pharmaceuticals and methods for medical 
treatment are research-based inventions. Patenting is essential to protect the 
development and commercialization of these inventions. This part will explain the 
criteria and procedure when applying for patent protection. 
In order for an invention to be patentable it must meet three prerequisites, being 
(1) novel, (2) associated with an inventive step and (3) subject to industrial 
applicability. For example, if no product with an identical combination of physical 
and functional features has been disclosed previously, it is to be regarded as novel. An 
assessment of the criteria of novelty includes a clarification of what has been available 
to the public previously. Likewise, an invention is associated with an invention step if 
a skilled person would not have had any expectation of success when making the 
invention. Thus, simple and predictable routine developments are not associated with 
an inventive step. In addition there are criteria that exempt inventions from 
patentability, e.g. for moral reasons or specific exclusions such as methods for human 
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cloning. Both inventions as products and methods can be patented, preventing third 
parties from: producing (for product patents), carrying out the method (for method 
patents), using, offer for sale, selling, importing the patented product or obtaining a 
product using the method for commercial purposes. A patent provides the right to 
exclude others from exercising the invention claimed in the patent for a period of 20 
years (Medicon Valley Academy, 2002). 
The first patent application filed by an inventor is priority-founding, describing 
the invention and establishes the right to claim priority under the Paris Convention. 
A priority-founding patent application should describe the invention in both general 
and more detailed terms. In case new important knowledge regarding the invention is 
acquired within the priority year, such aspects can be included in an updated patent 
application filed before the expiry of the priority year or described in a new priority-
founding patent application. A priority year is the period of 12 months after filing a 
priority-founding patent application (Ibid.).  
The main idea with the Paris Convention of 1883, the first international 
convention on intellectual property rights, was to ensure inventors protection on 
more than a national level. Under normal circumstances a patent cannot be filed in 
more than one country at the same time since it needs a translation and a patent 
attorney to handle the process. Obviously, filing a patent application in another 
country at a later date carries risks. For instance, the invention may have become 
public between the first and the second filing, which according to the novelty criteria 
causes a problem. The remedy was introduced in the Paris Convention, allowing for 
a priority period of one year for patents. Within that period, the applicant is entitled 
to file his application in another country and thus treated as if it was filed at the date 
of the first patent application, with regard to for instance novelty (Heath, 2000). 
However, seeking patent protection in more than one country requires 
individual applications for each country the inventor wishes to obtain patent 
protection in, without doubt a very burdensome and costly activity. The European 
Patent Convention (EPC) is on the other hand an exception in this matter, enabling 
the European Patent Office (EPO) to grant patents for all member states of the EPC 
if the applicant so wishes. Still there are no other regional systems as the EPC. The 
idea of the Patent Co-operation Treaty (PCT) of 1970 was to facilitate the filing of 
patents in more than one country (Ibid.). 
 
 
Figure 3.5 Patent application process (Medicon Valley Academy, 2002, p.31).     
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3.2.2. Patent strategy 
Levin et al. (1987) show the varying potential of patent rights to amplify 
appropriation of returns from innovation across industries. However, drug and 
chemical industries benefit from a tight appropriation regime where protection by 
patenting is an effective mechanism. To distinguish the type of industry with regards 
to patenting Merges & Nelson (1990) established two main types of technological 
industries, namely discrete and complex industries. While pharmaceuticals are an 
example of a discrete industry, semiconductors would constitute a complex industry.  
Reitzig (2004) studies the exercise of forming bulks of patents to protect an 
innovation. One type of bulk is called a ‘patent fence’, which in effort to enhance the 
value of the innovation is used to block competitors from producing competitive 
substitutes that can be easily patentable and exploited. Furthermore, the protection of 
a commercially exploitable product or process in a discrete technology would likely 
consist of a limited number of patents, whereas it would be comprised of numerous 
ones in a complex technology. For example in pharmaceuticals, the first-best use of 
patents is to exclude others from copying. In theory, there is no need for a patent 
fence in pharmaceuticals because substitutes for active molecules hardly ever exist. 
Exclusion should yield maximum returns on investment for the patentee unless access 
to complementary assets held by others is crucial and thus forcing the patentee to 
share the innovation.   
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4. Empirical results 
Presented in this chapter are the empirical findings of the case study. The first section 
describes the case study outline with interviewees and the relevance of their views for the 
study. The second section illustrates the thoughts concerning their roles as expressed by those 
interviewed belonging to a mixture of organizations that facilitate the technology transfer 
process. The third section portrays the case company, how it went through the technology 
transfer process and its continued development. 
4.1. Case study outline 
In order to conduct this case study, eight persons from different organizations were 
interviewed. As mentioned in the chapter on methodology, units of analysis and the 
data collection sources belong to the organizations or external agents taking part in 
the technology transfer process placed within a chosen entity, Innovationsbron Syd 
AB. Likewise they represent, with one exception, important contributors and 
stakeholders along the progressed pathway of the chosen case company, Cartela AB.  
Four of the interviewed professionals are active professionals at what can be 
considered a technology transfer entity, located at Ideon Science Park in Lund, 
Sweden. The technology transfer entity is structured as a business group and Sven-
Thore Holm is the CEO of the parent company, Innovationsbron Syd AB. 
Forskarpatent i Syd AB is one of the subsidiaries, where Sten Trolle is the working 
CEO. Adam Schatz is the Managing Director at Teknoseed AB, a second subsidiary, 
and Per Antonsson is a Business Advisor at a third, Teknopol AB.  
Evy Lundgren-Åkerlund is the inventor, founder and CEO of Cartela AB, and 
has experienced the technology transfer process as well as the subsequent struggle of 
building a start-up venture. Some interviewees have taken part in the birth and 
progression of Cartela AB to a larger extent than others. For instance Adam Schatz 
was for a significant period of time, a member of the board with Cartela AB. Per 
Antonsson was previously employed by Active Biotech AB and thereby was highly 
involved in this specific case company’s history. Sten Trolle was involved in the pre 
start-up period when Evy Lundgren-Åkerlund originally made a decision not to start 
a company of her own; a decision that was to be altered later on.  
In the process of commercializing research based technologies, intellectual 
property rights (IPR) are an essential aspect. External IPR bureaus are often consulted 
in the technology transfer process as well as in the continued effort of building a 
research based venture. Regarding external IPR expertise, units of analysis and data 
collection sources herein were Per-Thomas Karlsson, Managing Director of Wagner 
Zacco AB and John Karlström, Patent Attorney with Awapatent AB. With regards of 
relevance, Awapatent AB was the IPR bureau consulted when Cartela AB filed its 
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first patent application; on top Wagner Zacco AB is the leading IPR bureau in 
Scandinavia.   
4.2. Innovationsbron Syd AB 
In 1994, the Swedish government created Teknikbrostiftelsen in Lund, given the task 
of stimulating economic growth in the southern part of Sweden by capitalizing on 
knowledge created at universities in the region. Six corresponding organizations were 
set up in other parts of Sweden in the same year. In order to accomplish this difficult 
task Teknikbrostiftelsen focused their attention on three important areas. First, a key 
to achieving growth was to provide companies, with limited resources for conducting 
R&D themselves, with knowledge steamed from the universities. Secondly, they 
aimed to facilitate the commercialization of innovative ideas derived from university 
research. Finally, an emphasis was made on supporting and encouraging relations 
between the industry and the universities (Teknikbrostiftelsen i Lund, 2002). 
In order to fulfill the task Teknibrostiftelsen i Lund created three companies 
named Teknopol AB, Teknoseed AB and Forskarpatent i Syd AB. In 2005 
Teknibrostiftelsen, together with the Swedish Government and Industrifonden, 
created a new group named Innovationsbron AB. However, Innovationsbron AB is 
intended to function with the same purpose as its predecessor Teknikbrostiftelsen, 
and the three companies previously formed, now remain as subsidiaries of 
Innovationsbron Syd AB (Innovationsbron, 2005). 
Innovationbron Syd AB constantly receives a stream of individuals, commonly 
senior researchers and on rare occasion’s even students, proposing an idea or 
invention. However, to ensure that a steady stream of innovations and ideas flows 
into Innovationsbron Syd, an agreement has been made with Lund University’s 
department of trade and industry. The university department is hereby obliged to 
scout various institutions and faculties in search of promising new ideas. In other 
words, a prescreening is performed by the university with focus on the technology. 
Once a month representatives from both parties then gather to discuss the findings 
and decide whether any actions should be taken in order to facilitate technology 
transfer. If any idea is considered to be commercially feasible, Innovationsbron Syd 
offers these individuals two pathways to commercially exploit it. Either they sell or 
license their invention or they form a start-up company. Whichever option they 
desire it can be facilitated with the support of the subsidiaries of Innovationsbron 
Syd. 
4.2.1. Sell or license 
If the individual is not willing to form a start-up venture, yet is interested in 
exploiting the invention somehow, they can turn to Forskarpatent i Syd AB who will 
help to license or sell their idea to an industry actor, who in turn uses it to generate 
products or services. But first the idea or invention is immediately subject to a 
thorough investigation regarding its originality, i.e. what needs does it fulfill or which 
problem does it solve? Are there multiple solutions to the same problem? The next 
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question is to identify a potential customer or perhaps several customers, even 
different industry settings. In other words a commercial focus is applied to the 
invention before a patent application is formed. In short, Forskarpatent i Syd AB 
asses the invention and provides help applying for patent protection if deemed 
commercially viable. Subsequently the intellectual property right is sold for profit, by 
which Forskarpatent i Syd AB receives 50 % of the revenues in return for carrying 
the costs of filing the patent application plus bearing the uncertainty of not finding a 
buyer for the IPR. Simply put, Forskarpatent i Syd AB consider themselves as an 
agency, where the research community constitutes the supplier and the industry 
being the customer; the researcher receives royalties and so does Forskarpatent i Syd 
AB. 
However, this is a simplified scenario and there are of course several options for 
commercially exploiting research based inventions in an similar manner; like one 
example described to us where Forskarpatent i Syd AB formed a joint venture in Los 
Angeles, with American management and investors, instead of just licensing the IPR. 
The grounds behind the decision were the possibility of attaining venture capital with 
relative ease as well as favorable conditions for conducting research more efficiently 
there. Still, the rationale is to grant a researcher an opportunity of exploiting the 
invention even as they continue to conduct research, perhaps with the possibility of 
doing so on behalf of the company that acquires the invention.     
4.2.2. Forming a start-up 
Opting for the other pathway, founding a start-up venture, the individual then turns 
to Teknopol AB, which in broad terms provides assistance and mentorship when 
creating a viable business concept. As well as providing help in establishing useful 
contacts for ensuring sufficient funding and assembling a board of directors for the 
start-up. 
It is underlined that Teknopol AB do not actively manage a company, rather 
they provide the means for a researcher to become an entrepreneur. A fundamental 
prerequisite is that individuals have a confident drive, a certain state of mind where 
anything is possible and personal entrepreneurial capabilities in order for this to work 
out well. When carrying out its mentorship, an important task for Teknopol is to 
clarify the common nature of conducting business as well as what is needed from the 
founders. This clarification often results in despair when entrepreneurs realize how 
their invention is perceived from a venture capitalist’s perspective. Acquiring funding 
can be a harsh experience for entrepreneurs, especially in life science businesses. This 
may seem understandable, having venture capitalist bearing the financial risk. Yet the 
main objective for entrepreneurs is to hold on to as much shareholder equity as 
possible. 
Naturally, researchers who turn to Teknopol are more often focusing on the 
technology, having spent limited thought on the customer, market and product. 
Thus a crucial task in guiding the researcher to become an entrepreneur is asking 
questions such as: who is the customer, what gap in the market is this invention 
intended to fill, how much is the potential customer willing to pay? Depending on 
the composition of the product, market and customer, how will this start-up create 
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revenue? When working with clients Teknopol utilize a comprehensive matrix 
model, divided into technology, market and business on one dimension and the 
continuous development of the venture over time in the other dimension. This 
matrix is also presented in a surprisingly large frame that is actually given to 
entrepreneurs for them to use in their daily activities while continuing building their 
business. The matrix covers main aspects to keep in mind when forming the venture, 
thus allowing the entrepreneur a better and more balanced focus on all aspects. It is 
on the other hand described to us that this matrix is just a part of a more complex 
model including further detailed schemes, which can be used for evaluating the 
progress of a business. In these schemes different aspects are weighted separately and 
then aggregated; as a method of checking the current temperature so to speak.    
4.2.3. Funding 
Initial seed funding in these cases is often provided by Teknoseed AB. Their business 
concept is based on increasing the value in high technology companies by becoming a 
partner early on. While in general they enter start-ups very early, the level of 
involvement varies both in terms of capital invested and management support. In 
some companies they have even been forced to provide semi-operational 
management support. Though, a prerequisite for making an investment is that the 
start-up is managed by a determined, goal oriented entrepreneur. If the venture is 
lacking such an individual with enough drive, the startup is deemed to fail. In order 
to evaluate the entrepreneurs and the progression of a start-up, a number of 
subjective determinants are used to create an index. These determinants are broadly 
divided into different areas of focus such as organization, market and technology. In 
fact, Teknoseed performs a review of their portfolio once a month, from which an 
average number is derived for each company. As the management of Teknoseed have 
motorcycles as one of their personal interests, the numbers are expressed in their own 
speed metaphor, ranging between 0 and 200 kilometers per hour to emphasize the 
progress of a particular venture. The review also serves the purpose of providing an 
insight into the portfolio and the market as well as Teknoseed’s performance. 
Surprisingly any conclusions such as providing an estimate of potential market value 
etc. are not drawn from the review. Nevertheless Teknoseed finds the actual 
reviewing process very valuable since it allows everyone to reflect and analyze every 
company in a structured manner. 
From Teknoseed’s point of view, there are many early stage ideas with potential 
as well as many traditional venture capitalists, however there is nothing in between 
and thus this is the gap that their business model is trying to fill. Teknoseed’s 
resources are nonetheless limited and the organization is dependent on acquiring 
additional funding for the startups, whereas Teknoseed can make an exit within 3 to 
7 years. During the process of searching for additional capital and promoting a start-
up, the network and external contacts are essential. With this in mind it is also 
expressed that Teknoseed is simply the organization that stitches together a financial 
solution and finds the competences needed to achieve success.  
In the usual manner, prior to any investments being made, a due diligence and 
more importantly a freedom to operate analysis is performed. If the analysis proves 
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that there are no obstacles, a technological review where potential risks are identified 
is performed, followed by the creation of a project plan with milestones. The purpose 
of working towards milestones is to monitor the progression and whenever a 
milestone is achieved a potential risk has been minimized. The injection of capital is 
also managed in conjunction with milestones reached. 
4.2.4. The rationale of patenting 
Patenting is necessary to address when dealing with technology rich inventions, either 
when to be licensed or continuously developed in a start-up. At Teknopol they 
recognize patenting as a key component of extracting value in start-ups and the start-
up process includes an assessment of the possibility for being granted a patent. 
Similarly, patenting is regarded as an important component in Teknoseed’s concept, 
although there are other components of equal or more importance. The most 
important factor is regarded to be the human attitude and capability, yet no 
investments are made in companies without viable patent strategies. It is underlined 
that the Life Science area is quite peculiar, where patenting has a more central role in 
facilitating value. Nevertheless, the individual entrepreneur and the invention’s 
ability to bridge a gap in the market are the key ingredients. 
Of course, Forskarpatent i Syd strive towards producing patents with great 
commercial potential. It is suggested that the best approach is aiming for the creation 
of a very broad all encompassing patent, which to a great extent prohibits and limits 
the competitors from releasing similar products. It is also important to aim high, thus 
writing the application with as broad patent claims as possible, since the boundaries 
are not known until they are breached. The consequences of having research results 
publicized are also emphasized, since a publication limits others from acquiring a 
patent. However, a troubling phenomenon is when a competitor or any other 
industry actor for that matter, on rare occasions is able to patent, for example in life 
science, a method for applying a patented substance to a patient. In such cases, the 
two patent holders are mutually dependent on each other to conduct business and as 
a result of this cross-licensing commonly becomes the solution. 
The following is an example of the potential risk associated with achieving an 
inadequate level of control. One of Wagner Zacco’s clients who had years of 
experience in patenting its inventions suddenly received a notice from the patent and 
registration office, claiming that the company’s operations was infringing on another 
patent, although the company could not realize why. Apparently a company 
representative had attended a research conference where he had revealed a process of 
applying a certain compound; however a supplier of this compound was also 
attending the same conference. The supplier then applied for a patent regarding the 
process and as a consequence Wagner Zacco’s client became dependent on the 
supplier, thus were forced to pay a royalty. This example stresses and visualizes the 
importance of achieving control and answering questions such as; what, when, how 
and who should be responsible for patenting? 
Patenting research based inventions comes with a slight absurdity. First of all, 
breakthrough discoveries are naturally subject for publishing in scientific journals, yet 
one needs to apply for patent protection before it is published, in order to fulfill the 
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novel criteria. Even if a researcher submits the application before publicizing, this 
sometimes creates additional problems when the researcher outlines how this 
achievement could have been reached by alternative means; undermining his or her 
own patent application by reducing the inventive step.  
4.2.5. Patenting done wisely 
When it comes to patenting a key is to link the business concept with the patenting 
strategy and it is here that problems may arise, since it in many cases is a question of 
financial resources.  The limitation of available funds often leads to a patent 
application which might not realize the innovations full potential. Patent protection 
apparently being a very abstract phenomenon, various analogs and metaphors has 
been described to us.  
Sten Trolle used the metaphor of a small plant when describing an invention; a 
fragile plant that can be squashed rapidly without much effort unless well protected 
by a patent. The inexperienced researcher who applies for patent protection may 
write a patent claim that constitutes a rather small roof covering the plant (figure 
4.1). However the competitors can plant an entire forest around it, which is just as 
effective to suffocate the plant. To resolve this, a large roof (1) as well as several 
subsequent medium-sized ones (2, 3, 4) has to be constructed in order to cover the 
entire field on which the plant grows, i.e. several claims varying in width. 
Figure 4.1 Scope of patent claims (Sten Trolle, 2005). 
 
Another interviewee makes an analogy with the process of hanging a painting on a 
wall. If an individual invents a method of hanging up a painting using a thread and 
nail, a patent application should not be limited to using just those components. The 
patent would then be easy to circumvent since a nail easily can be replaced with a 
screw or even a stick, and it is this way of thinking that patent consultants work with. 
The initial question that needs to be answered is; what is the actual invention? Thus 
the aim is to create a well defined patent, containing a minimum of well articulated 
claims, yet still encompassing other possible means to achieve the inventions purpose. 
In other words if a patent is to be useful it has to have clear boundaries and a sharp 
definition that can easily be communicated in a court room when countering 
infringements. 
Patenting can be further visualized in a model, described to us by Per Tomas 
Karlsson at Wagner Zacco AB, incorporating the legal, time and technology 
dimensions. In the model the base area represents the legal scope with a time span of 
20 years, shown by the height of the cylinder. In order to survive the height of the 
1. 
2. 
3.
4.
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cylinder has to constantly increase, through development of new technology followed 
by patent protection within the confines of the base. As time progresses new cylinders 
are added and eventually the legal scope consists of large number of narrow patents, 
thus a large part of the technology is unprotected and available to all. However, those 
companies who are taking advantage of the formerly protected technology are still 
dependent of the narrow patents, or peaks. As an example; think of the combustion 
engine which is to a large extent based on unprotected technology such as pistons, 
cylinders, valves etc. However, new patented technology in the form of, direct fuel 
injection has emerged and offers substantial advantages to the consumers. Even 
though a large extent of the technology is unprotected the engine producers, wishing 
to create superior engines, are still dependent on the fuel injection patent which can 
be illustrated as a narrow peak. 
 
Figure 4.2 Cylinder model (Per Tomas Karlsson, 2005). 
 
At this point a technology shift may occur, rendering previous patents useless, as in 
the case of combustion engines where radically new technology in the form of fuel 
cells is entering the market. Consequently, new cylinders are added outside the initial 
patent’s legal scope as depicted in figure 4.2.  The model places an emphasis on the 
importance of renewal and implies that even though a comprehensive patent has 
been obtained it is at all times necessary to scan the industry for potential threats, 
identifying customer needs and finding new paths to follow. Consequently 
intellectual property management is, and always will be, dynamic in nature where 
prerequisites are bound to change. The aim is to make products profitable for a long 
time through the creation of a carefully considered strategy of safeguarding. 
Sten Trolle also showed us a model that describes the scope of claims as well as 
continuous patenting over time. The perspective was described using the metaphor of 
a road, where roadblocks in the form of patents are built in order to hinder the 
competitors from advancing. As illustrated in figure 4.3 the importance of having a 
strong and wide initial roadblock is stressed, i.e. having clear and encompassing 
patent claims. If not, the road is easy to access by inventing around the initial patent, 
comparable with the small roof covering the plant. Yet, there can be a possibility to 
reach the destination, such as an effective treatment of a  
20 years
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Figure 4.3 Roadblock model (Sten Trolle, 2005). 
 
disease, via an optional route, thus achieving the same benefits as the original road. 
This is similar to the technology shift displayed in the cylinder model, figure 4.2. 
Furthermore, it is emphasized that the competitors may have the option of placing a 
roadblock of their own further ahead on the road, for example the application of a 
patented substance. Thus making the two competitors mutually dependent on each 
other, with cross licensing as the most common solution. 
4.3. Cartela AB 
Cartela was founded in September 2000 by Associate professor Evy Lundgren-
Åkerlund, Professor Karl-Olof Borg and Professor Stefan Lohmander. However, 
Cartela’s history stretches further back in time and it all emerged from Lundgren-
Åkerlund discovery of the integrin alpha10beta1 in the mid 1990s. An integrin is a 
protein, which in this case is placed on the chondrocytes in cartilage. Their function 
as signaling molecules point to their potential as therapeutic and diagnostic targets in 
arthritic disease treatment. 
The case of Cartela is rather peculiar since the inventor and founder still is the 
CEO. On the other hand, several interviewees underlined that without Lundgren-
Åkerlund’s knowledge and personal capabilities, Cartela would never have existed. 
Whilst conducting the interviews it became evident that she encompassed an 
undisputed entrepreneurial drive. 
4.3.1. Discovery, patenting and sale to Active Biotech 
The discovery of integrin alpha10beta1 was made when Lundgren-Åkerlund still 
conducted research at Lund University. The potential of this integrin was recognized 
very early, as a means of diagnosing and treating arthritic disease. Consequently a 
need for patent protection appeared and more or less by accident she came in contact 
with Forskarpatent, who provided assistance and pointed her in the right direction. 
As a result a patent application came into existence. The description of the invention 
and the patent claims were written by Lundgren-Åkerlund herself. Since 
Optional route
Road blocks Competitor’s patent
Destination 
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improvements to a patent could be made within a year following the original 
application, the application was aimed at merely providing basic protection.  
Soon after in 1999 the patent was with the help of Forskarpatent sold to Active 
Biotech, and she joined as a researcher. This solution provided Lundgren-Åkerlund 
also with the essential means for conducting further research and development of the 
idea, thus allowing its true potential to be realized. Yet, the basic protection of the 
patent rendered a need for rewriting it. This was done at Active Biotech, and in the 
end the number of claims was almost ten folded. 
4.3.2. Sale back, forming a start-up and seed capital 
However, a change in Active Biotech’s strategic direction put the project of integrin 
alpha 10 beta 1 on hold. Having met new people and realizing that this may be 
possible to achieve by other means, Lundgren-Åkerlund also decided to continue 
with the idea on her own. She had also met and worked with Per Antonsson at Active 
Biotech, and as a result she turned to Teknopol, where Antonsson now worked, 
receiving assistance with general advice in writing a business concept, as well as 
clarifying the investors’ expectations. They also helped her with an initial loan and 
together with Teknossed, brought in an additional investor, Volito. With assistance 
from Forskarpatent, the IPRs were then repurchased and Cartela was founded. 
Cartela was already from the start focused around a solid idea and has managed 
to sustain the same vision and strategic direction ever since. Nevertheless, it takes 
more than just a solid idea to become successful and survive in a harsh environment 
such as the Biotech industry. From Cartela’s point of view, the human resources are 
the key to survive and ultimately succeed. Therefore the employees are carefully 
handpicked from both academia and industry. Recruiting takes a “hire for attitude 
and train for skills” approach, since the company is very small and teamwork is the 
norm. Capital is injected on a milestone basis and it is important that the individuals 
are aware of that, to handle the pressure knowing that the company is dependent on 
its investors.  
In the case of Cartela, capital was initially provided by Teknoseed who entered at 
a very early stage together with another investor named Volito. This capital was 
essential for allowing the company to survive and Teknoseed states that they were 
particularly involved in building the financial solution and took the lead 
responsibility. On the other hand, Lundgren-Åkerlund claims that she has been 
struggling since day one to attract capital and that it takes a good salesman in order 
to do so. Her most valuable assistance in this task is the patent portfolio. 
Nevertheless, the process of finding and convincing venture capitalists to invest is 
placed high on Cartela’s agenda. It is a constant battle and it is essential to convince 
the investors that the concept is plausible although it might take several years to 
reach. Cartela strive towards the goal of using their target molecule, integrin alpha 10 
beta 1, as a means of treating arthritic disease. In order to attract additional investors, 
a great extent of groundwork is required. A solid proof of principle is desirable, where 
the substance is validated through a biomodel, e.g. the substance has documented 
effect on mice, since it is a strong signal of future potential.  
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Yet, Teknoseed is still involved to some extent as an equity holder and will 
eventually make an exit when new investors enter. According to Teknoseed, the most 
plausible exit is that a large pharmaceutical company will acquire Cartela and a more 
complex exit is a merger between Cartela and some other entity in order to enter the 
stock exchange.  
4.3.3. Business development and partnering 
It is however stated that the business model used since the start has been less suitable 
when it comes to attracting large amounts of capital, yet Cartela has found it to be a 
realistic model. A strategic change is now taking place, now aiming to bring 
substances into the first clinical phases. Previously, Cartela focused on developing 
substances within preclinical trials, e.g. proving the concept on animals, and the 
reason for this change is that preclinical substances are substantially undervalued if 
sold, in contrast to a substance that has reached clinical trials. Naturally a strategy 
change of this magnitude requires additional funds, which Lundgren-Åkerlund now 
is searching for. Paradoxically, following the new strategy and the acquisition of large 
amounts of capital may be easier to ensure than gathering smaller amounts while 
pursuing the original strategy.  
To a large extent Cartela relies on the founders personal network, which has been 
developed during several years of work within the life science area prior to Cartela’s 
existence. Lundgren-Åkerlund, in the role of being a business developer, has used her 
network and now reestablished contacts with several of the larger pharmaceutical 
companies such as Astra, Pfizer, GlaxoSmithKleine and Novartis; perceived as 
customers and not competitors. Cartela has managed to build a unique knowledge 
mass, and it is most likely that a trade-sale to a larger corporation will take place at 
some point in time; mainly due to the fact that Cartela was first with this approach in 
this particular field with its attractive market lacking effective products for therapy of 
arthritic disease. Using the ability to create relations, partnering with other 
companies such as Bioinvent further enabled Cartela to increase its knowledge mass 
since it ensured access to a comprehensive set of antibodies used for their continuous 
research.  
Cartela is a company which falls under the definition of a knowledge company. 
Since its value is derived from the minds of the individuals and in order to legally 
protect the commercially exploitable value, a number of patents have been 
constructed.  
As previously mentioned an initial application was created by Lundgren-
Åkerlund in conjunction with Forskarpatent followed by an updated application. 
Currently there are six published patents, which all have been created with the use of 
external agents, namely Awapatent and Albihns. Recently Cartela also decided to hire 
a former employee of Albihns who specializes in intellectual property rights, and this 
is intended to provide Cartela with a more strategic approach to patenting. Having 
an intellectual property rights specialist is considered essential since it facilitates for a 
higher level of codification of knowledge, greater insight into the patent portfolios of 
competitors as well as monitoring possible infringements on Cartela’s patents. The 
task will predominantly include developing a close working relationship with the 
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company’s researchers, as a means of identifying new discoveries and evaluating at a 
very early stage if and what to patent.  
Cartela consists of a mere 13 individuals of which one is dedicated to managing 
patents, this proving the level of commitment to patenting. The increased focus is 
viewed as a part of the maturity process where it is natural to begin with a defensive 
approach followed by a more offensive approach. An offensive approach is from 
Cartela’s point of view more appropriate when having accumulated a larger portfolio 
of patents and when a more aggressive overall strategy is used.  
As in many industries it is possible to circumvent the patents, however the 
human body sets limits and even if it is possible to find other integrins with similar 
functions, the patents cannot be completely circumvented. It may also be possible to 
find other ways of treating arthritic disease, however Cartela’s approach is unique and 
efficiently legally protected. Lundgren-Åkerlund affirms: “…without patents we 
would not have anything, we would not be able to attract any capital”.  
4.3.4. Patent portfolio 
Cartela’s patent portfolio is built around the initial patent which acts as an umbrella 
under which the other more narrow patents emerge. The narrow patents provide 
even greater protection around the central patent, preventing competitors from 
utilizing alpha 10 beta 1 as a target molecule in several ways. If however an industry 
actor applied for a patent where the usage of Cartela’s integrin as a target is deployed, 
they will become dependent on Cartela. 
As of today, Cartela has six published patents in its portfolio (table 4.1) and the 
first page of each patent, including abstract, is available in the appendix. But despite 
having these patents regarding the use of integrin alpha 10 beta 1 as a target 
molecule, Cartela do not necessarily intend to further develop all the ideas included 
in the patents by themselves. To be able to reach their vision of developing a 
treatment for arthritic disease, Cartela needs to keep a narrow focus and continue to 
conduct research in a limited scope. Yet, related patents will bring a great deal of 
value through licensing or partnering, and a key note is that all the patents form an 
important indicator of strength and future potential in the eyes of investors.  
 
No. Title Priority date 
1 An integrin heterodimer and a subunit thereof (alpha10beta1) April 1998 
2 An integrin heterodimer and a alpha subunit thereof (alpha11beta1) June 1999 
3 Knockout mice and their use April 2002 
4 Marker for stem cells and their use June 2002 
5 Methods and uses of the integrin alpha 10 chain, for preventing progression atherosclerosis plaque formation June 2002 
6 New monoclonal antibody capable of binding integrin alpha 10 beta 1 April 2003 
 
Table 4.1 Cartela’s patent portfolio (published) 
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The first patent is the foundational patent that was written by Evy in 1998, soon 
sold to Active Biotech and later repurchased when Cartela was to be started. The 
foundational patent (1) is very encompassing; the sequence in itself for one but also 
the various ideas for possible applications. Such encompassing claims would not be 
approved in a patent application if it was to be submitted today. The set of guidelines 
have become limited since then. Today you would be forced to withdraw some 
claims and save for later usage. 
The second patent protects the usage of another closely related integrin, alpha 11 
beta 1. This integrin was discovered by a research colleague of Evy and the patent was 
later purchased by Cartela. 
The third patent is interesting since it protects the use of mice from which the 
gene for integrin alpha 10 beta 1 has been removed. The intent is to use the mice as a 
model for studying possible diseases that mice without the gene might develop; as a 
consequence it effectively blocks the competitors from performing similar research. 
Although in the event that these mice become important models for performing 
some type of screening, Cartela can capture revenue from licensing. 
The fourth patent protects the usage of alpha 10 beta 1 as an efficient marker for 
stem cells, enabling the sorting of stem cells from bone marrow to make new tissue. 
For instance, one could gather stem cells in a simple step with this marker and 
subsequently make cartilage in order to heal cartilage damage. Still, this area is not in 
Cartela’s focal area of research and they are now seeking a partner to license this 
usage of alpha 10 beta 1, yielding additional revenue from licensing.    
The idea protected in the fifth patent is not yet developed, but may turn out to 
be very interesting in the area of atherosclerosis (the same area of treatment as for 
substances developed by Esperion Therapeutics). The idea came out of a 
collaborative project with Lund University. The discovery was that plaque in veins 
begins to produce cartilage molecules; for some reason the cells in a vein start 
performing the wrong task. Possibly, alpha 10 beta 1 can be an effective target used 
to prevent atherosclerosis, plaque in the veins. If that becomes the case, this is 
something most likely to be out licensed as well. 
The sixth patent constitutes an important milestone reached for Cartela. The 
patent protects an antibody that binds to alpha 10 beta 1 and can send a signal 
through the integrin to the cell core. An antibody can be a product in itself; it is seen 
as a tool in the attempt to manipulate the cell. Finding a suitable antibody has 
demanded years of research and was made possible through the partnering with 
Bioinvent, who provided the technology to develop human antibodies.  
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5. Discussion and conclusions 
This chapter presents an analytical discussion on the empirical results and how we perceive 
the interaction of intellectual capital components. This includes a number of plausible 
conclusions on how innovation capital might be viewed and portrayed in a technology rich 
start-up over a longer period of time.  
5.1. Analytical discussion – Elevating innovation 
capital 
To recapture, in the theoretical analytical framework it is evident that intellectual 
capital is comprised of three forms of capital which have to interact in order to 
achieve value; with the interaction illustrated in the IC value platform and the 
corresponding concept of generative assets in the intangible value chain. It is also 
suggested that innovation capital is generated in this interaction and that it, as a part 
of the IC landscape, should be regarded as the future earnings potential. 
Apprehending this notion, we compare this to the idea of commercially exploitable 
assets and the derived marked value added, shown in the intangible value chain. With 
these concepts at hand we may portray how this IC rationale is evident in the case. 
5.1.1. Technology Transfer – deploying generative assets 
Initially Evy Lundgren-Åkerlund turned to Innovationsbron Syd and Forskarpatent i 
Syd AB, carrying an embryo of innovation capital, opting for the pathway of 
licensing her invention. Thus, in order to leverage the value of the idea, 
Forskarpatent i Syd AB triggered and provided the means of interaction through the 
selling of the invention to Active Biotech. As a consequence the capital forms needed 
to foster the embryo became accessible.  
With the value platform in mind, Active Biotech’s processes, offices and 
equipment represented structural capital; the human capital was embodied in Active 
Biotech’s employees assigned to the project as well as Lundgren-Åkerlund joining the 
company. The relation capital came with the organizations existing relations. With 
these forms of capital, an adequate environment emerged in which the embryo could 
be developed. In our perspective, Forskarpatent i Syd thus found the desirable 
generative assets needed to embrace the embryo and continue to build innovation 
capital. Yet, the renewal capability was already present to a large extent, embodied in 
the preexisting IC of Active Biotech. 
However, when Active Biotech altered their strategy the embryo did no longer fit 
within the research portfolio. Consequently the intent was lost, leaving Lundgren-
Åkerlund with her invention without the support of neither form of capital. This 
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became even more evident when Lundgren-Åkerlund left Active Biotech and 
repurchased the patent, basically returning to square one. 
In order to reinstate the embryo in a fostering environment new generative assets 
needed to be gathered, and Lundgren-Åkerlund again turned to Innovationsbron 
Syd.  In this sense the technology transfer entity facilitates the deployment of human, 
structural and relationship capital, subsequently establishing a platform where 
generative assets can be formed as well as interact; enabling the elevation of 
innovation capital. For example Teknoseed, in addition to capital injection, also 
provided human, structural and relational capital; having Adam Schatz as a board 
member providing management support, translates to human- and structural capital.  
Similarly Teknopol assisted with clarifying the terms expected by venture 
capitalists, initially Volito, bettering the conditions for Lundgren-Åkerlund in 
building the relational capital of Cartela. Obviously the platform establishes the right 
conditions to form generative assets and thus the potential of building commercially 
exploitable assets. Nevertheless the platform is bound to change when the startup is 
expected to self perpetuate, thus altering the composition of generative assets, i.e. 
bringing in additional human capital and improving structural capital. Yet, the 
platform is highly dependent of the initial human and relational capital carried by 
Lundgren-Åkerlund, stressing the importance of the entrepreneur’s capability. 
5.1.2. Interaction between generative assets 
The story of Cartela reveals how the three forms of capital interact and thereby the 
growth of innovation capital. Lundgren-Åkerlund has handpicked employees with 
the intent of creating a tightly integrated team able to work under less than perfect 
conditions, building the human capital. Of course employees need to be competent 
but the right attitude is stressed, revealing that human capital is more than just 
knowledge. These employees are multiplied with structural capital through tightly 
integrated work processes. Research results, goals and the vision of reaching a 
therapeutic product, are routinely evaluated and shared amongst employees, thereby 
incorporated into work processes. 
In coherence with the conclusions of Zahra (1996), we may observe that the 
founder of Cartela places a considerable interest in the fate of the venture and that a 
sense of risk taking is present. The autonomous venture clearly benefits from the 
undisputed entrepreneurial drive encompassed in the human capital of the founder.  
Collaborative research conducted with university partners as well as BioInvent 
constitutes the impact of relational capital. The border between relations belonging 
to the organization and the individual is somewhat fuzzy. An example of this 
phenomenon is Lundgren-Åkerlund’s pre-existing relations with individuals working 
for large pharmaceutical companies, in this stetting constituting a potential buyer of 
Cartela. Similarly, relations with investors such as Teknoseed would be regarded as 
relationships belonging to the organization through contractual agreements. Yet, 
attracting capital might be highly dependent on personal relations. Having 
established a relationship with a partner such as BioInvent, is also a strong indicator 
of organizational fitness and capability in establishing collaborative research 
partnerships.   
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Evidently, Cartela has built upon the embryo of innovation capital, producing 
new inventions and aggregating a mass of knowledge, thus showing their renewal 
capability finally embodied in several patents. The accumulated value of the 
innovation capital, i.e. the market value added, is the combined effect of two more or 
less correlated occurrences; reduced uncertainty and elevated knowledge mass. While 
the aim of conducting research is to accumulate knowledge and reach proof of 
concept, a positive side effect is reduced uncertainty which in turn yields a lower risk 
premium. The concept is simple, reducing the risk premium equals an increased 
market value and reduced uncertainty also aids the acquirement of additional 
funding. A fundamental prerequisite of reducing uncertainty is a buttressing of the 
innovation capital via thorough patenting. The importance of transforming 
knowledge into patents is as well reflected in Cartela who recently employed an 
intellectual property specialist with the sole purpose of facilitating a higher level of 
strategic patenting activities. 
5.1.3. Analytical discussion summary 
Having discussed the different occurrences that take part in the progression of 
innovation capital, it enables us to distinguish the primary aspects and their 
interrelation, illustrated in figure 5.1 and 5.2. 
The technology transfer entity provides the means to establish a platform where 
the entrepreneur can build its own generative assets. By handpicking its human 
capital, constructing work processes and establishing relations with external parties, 
the firm starts building the value platform and the interaction commences. Whilst 
the interaction, working towards the vision of a therapeutic product, is increased, the 
ability of renewal is improved and results start to amass, thus innovation capital is 
elevated. The results may be seen as an accumulated mass of explicit knowledge. The 
mass is in need of safeguarding in order to appropriate the rents from innovation and 
hence the use of patent protection is put into effect, turning intellectual assets into 
intellectual property rights. 
The value from this is derived from two aspects: commercial value of safeguarded 
explicit knowledge mass (SEKM) and degree of uncertainty (DoU). This matches up 
to the corporate valuing mechanism, market value added, argued to be the most 
appropriate in the intangible value chain. Whereas the safeguarded explicit 
knowledge mass translates into potential commercial value (PCV), uncertainty degree 
renders a risk premium (RP). Thus, market value added (MVA) can be easily 
explained: MVA = PCV – RP. 
 
 
Figure 5.1 Interrelation of primary elements (Alvén & Ekelund, 2006). 
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Although the interrelations of primary elements portray the derived market value 
added as well as the awareness of an ultimate product vision, we may simplify the 
elements and show this in the combined perspective of the intangible value chain and 
the IC value platform (figure 5.2).  
 
Figure 5.2 The value chain perspective (Alvén & Ekelund, 2006). 
 
Taking into account the impact of time, we clearly see the benefits of forming a 
start-up, cultivating the innovation capital embryo over time. Several of the 
interviewees frequently underlined the economic gain to be seized by forming an 
autonomous start-up, compared to the option of licensing the innovation. Again, the 
impact of reduced risk by continuously building on the innovation and thereby 
obtaining proof of the fundamental concepts potential is apparent. Naturally, the 
realized economic gain to be captured by the inventor is substantially reduced when 
opting for a licensing solution. The whole matter is a question of who wants to bare 
the risk encompassed in an unproven innovation and carry the cost of proving its 
potential, whether it’s the inventor or a licensing partner.  
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6. Visualizing innovation capital 
Our concluding thoughts on the interaction between generative assets, translated into the 
concept of innovation capital, can be summarized into an illustrative comprehensive 
model portraying the value and progression of innovation capital. The value perspective of 
the model emphasizes the impact of time and uncertainty. We also discuss the relevance 
and explanatory power of this model. 
6.1. A model for visualizing innovation capital 
The model contains two mirrored perspectives describing innovation capital and 
derived market value added. Both dimensions are highly subjective in nature since 
estimates are based on perceived elevation.  
The innovation perspective (figure 6.1) depicts the agglomerated explicit 
knowledge mass and the continuous buttressing of patents, safeguarding the 
intellectual assets. The accumulated knowledge mass indicates previous renewal 
capability as well as future efforts needed to reach the desired milestones. Knowledge 
in this aspect refers to intellectual assets with potential commercial value that can 
attain legal protection, such as the discovered usage of a specific integrin in treating 
arthritics. The innovation perspective is an agglomerated view of total achieved 
knowledge mass; this can of course be dissected into separate research directions, 
however still based on a foundational innovation. 
 
 
 
Figure 6.1 The perspective of renewal and safeguarding (Alvén & Ekelund, 2006). 
 
In figure 6.1, intended to visualize the innovation perspective, the various patents 
(see appendix) related to Cartela are depicted. The illustration of patents is largely 
based on the patenting models described in the empirical material, but it also 
includes the characteristics of patenting, such as the priority year and the limited 
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lifetime, described in the theoretical framework. Building our illustration rationale 
upon the ‘cylinder model’ (figure 4.2) as well as the model illustrating the scope of 
patent claims (figure 4.1); we can depict both a scope and time dimension in figure 
6.1. Yet, since the height constitutes a technological – legal scope, the height is highly 
subjective due to the difficulty of providing an accurate measure related to knowledge 
mass. Although it is evident that the initial patent should represent a larger share of 
safeguarded knowledge mass since it builds upon several years of research, prior to 
the filing of a patent application, as well as it represents the foundational invention.  
As previously mentioned, new important knowledge acquired within the priority 
year, can be included in an updated patent application thus elevating the height 
during the course of a year. As an example; in the case of Cartela several changes were 
made to the initial application resulting in an increase of the legal scope represented 
by the shaded area exceeding the knowledge mass graph. Nevertheless the figure 
illustrates Cartela’s effort of safeguarding the knowledge mass and thereby 
transforming knowledge into commercially exploitable assets. 
Increasing knowledge mass is obviously dependent on various different aspects, 
yet on a whole it would be considered a result of the interaction between the 
generative assets. In the case of Cartela this is represented by the continuous work 
towards finding a suitable therapeutic method, in essence multiplying the human 
capital with structural capital. For example Cartela’s current search for a suitable 
antibody that can transmit a signal through the integrin to the cell core, where 
teamwork, routines and the knowledge of the employees constitute the main active 
ingredients. Another example would be how this search is amplified by partnering 
with BioInvent, assuring a vast set of antibodies, further enabling the continued 
increase of knowledge mass. The illustration of a knowledge mass as a curve in figure 
6.1 may also display a lack of innovation. In this sense a flat line would constitute a 
situation where no new knowledge is agglomerated. Likewise, if the line progresses 
upwards but lack patent protection, thus leaving the knowledge area without 
safeguarding, this indicates a failure in the management of innovation capital.   
Since the innovation perspective highlights commercially exploitable assets, the 
perspective of derived market value added (figure 6.2) would be more or less a 
mirrored image. Evident in the empirical findings is the impact of uncertainty on 
market value. By elevating and buttressing the knowledge mass uncertainty is reduced 
thereby efficiently lowering the risk premium. Increasing the knowledge thus lowers 
the risk premium in an interrelated manner.  
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Figure 6.2  The value perspective – derived market value added (Alvén & Ekelund, 2006). 
 
The value scheme underlines the gain of fostering the innovation capital embryo in a 
start-up venture. Market value added is almost multiplied two fold per additional 
unit of innovation. However this stresses the importance of continued and intelligent 
patenting of innovation thus reducing uncertainty for the potential buyer, much like 
the rationale described in the intangible value chain. Without this safeguarding, this 
risk premium is not lowered, on the contrary it may even be increased as a result of 
poor management. An example of this is the hostile patenting of a coating method, 
being described in the empirical results, which led to a cross licensing situation, 
certainly reducing the economic gain.  
The importance of intelligent patenting is frequently underlined in the empirical 
findings, especially through the visualized metaphors. This also stresses the 
importance of a continued renewal capability since patent protection is limited to 20 
years. In essence having an updated patent portfolio enables an appropriation of 
economic rents from achieved innovation.  
6.1.1. Explanatory power and relevance 
After reviewing the model, we have identified two possible limitations. The first one 
is with regards to the time dimension. Naturally the model is aimed at describing the 
emergence and growth of innovation capital over a longer time span, where striving 
towards reaching one or a few set milestones is evident. Thus, applying the model to 
a technology setting with a time span less than two or three years would be more or 
less pointless.    
The second limitation is on a different note. In accordance with theory the use of 
patenting and the forming of bulks of patents in order to safeguard the innovation 
capital is not done as a means of blocking competitors from producing competitive 
substitutes, i.e. patent fences are not constructed. This is predominantly due to the 
lack of knowledge regarding which research path will lead to the most suitable and 
effective therapeutic method or product, since substitutes for active molecules or 
equally efficient antibodies hardly ever exist; the nature of the human body cannot be 
reinvented. Consequently, each industry player places its faith in their own research, 
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believing it is the correct path in achieving the most efficient treatment. This is also 
illustrated in the proposed model for innovation capital, where patent safeguarding is 
fairly simplistic without the usage of sophisticated patenting strategies to hinder 
competitors from making substitutes. In short, the usage only portrays an efficient 
safeguarding of the proprietary therapeutic method over time. This leads to the fact 
that if the innovation capital model would be applied to a complex technology 
industry, where more sophisticated strategies for constructing patent protection are 
more common, the illustration of patent buttressing would lack ways to describe the 
usage of strategies such as a patent fence. Yet, as we also have shown in the empirical 
findings, the use of such patent strategies is most likely not being made by a start-up 
firm due to limited resources. 
The value scheme incorporates the concept of risk premium, predominantly 
lowered by reducing uncertainty through the build up and efficient safeguarding of 
the knowledge mass. However, the concept of uncertainty may be reduced by other 
means than increasing knowledge mass. For instance, assuring linkage with an 
important and prestigious investor, the uncertainty might appear as lowered when a 
potential buyer favors a company having a certain source of funding. Herein, 
uncertainty lies in the eyes of the beholder. 
Moreover, the amount of value derived from innovation is most likely to be 
dependent on the specific idea and innovation, of course varying in its potential of 
achieving a market blockbuster effect. For example, this would differ with regards to 
the specific part of the biotech industry and even therapeutic area. However, this is a 
fundamental prerequisite for even founding a start-up; ensuring a sufficient market 
potential. Hence, the model is not foolproof in the sense that although innovation is 
agglomerated and safeguarded sufficiently, it is not guaranteed that it translates into 
high market value added. As mentioned, market value added is a subjective concept 
in nature and the value progression estimation in figure 6.2 is here treated as the 
phenomenon occurring in a stock market valuation, involving multiple factors being 
treated with subjective measures. However, the fact that the study supports a market 
value added rationale to be used in an IC context is apparent in this industry setting 
where no actual profit is being made. With the intrinsic condition followed by 
product development lasting several years, economic value added is not a viable 
measure. This in turn supports Ahonen’s (2000) intangible value chain perspective.   
 Finally, with regards to the relevance of the model in relation to previous work, 
the model adds a clarifying angle on IC and innovation capital in a longitudinal 
dimension as well as the buttressed safeguarding of commercially exploitable assets. 
Of course the deployment of the model is highly subjective in nature, but still 
provides a mental measuring framework in the process of managing the firm’s 
intangible value progression in a manner that is similar to what Mouritsen (2004) 
constitutes as the purpose of understanding IC. IC is more concerned about value as 
a verb, more about the process of valuing than to determine a value. IC is “… not to 
be evaluated on its reflection of reality but rather on its ability to help actors 
transform their reality” (Mouritsen, 2004, p.257).    
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